These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11466694)

  • 1. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma.
    Natsume T; Kobayashi M; Fujimoto S
    Cancer; 2001 Jul; 92(2):386-94. PubMed ID: 11466694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo.
    Natsume T; Koh Y; Kobayashi M; Fukumoto H; Takahashi F; Nakamura T; Ohe Y; Saijo N; Nishio K
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):35-47. PubMed ID: 11855751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.
    Watanabe J; Natsume T; Fujio N; Miyasaka K; Kobayashi M
    Apoptosis; 2000 Oct; 5(4):345-53. PubMed ID: 11227216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
    Lai SL; Perng RP; Hwang J
    J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes.
    Natsume T; Nakamura T; Koh Y; Kobayashi M; Saijo N; Nishio K
    Invest New Drugs; 2001; 19(4):293-302. PubMed ID: 11561688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
    Natsume T; Watanabe J; Koh Y; Fujio N; Ohe Y; Horiuchi T; Saijo N; Nishio K; Kobayashi M
    Cancer Sci; 2003 Sep; 94(9):826-33. PubMed ID: 12967483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer.
    Maniwa Y; Yoshimura M; Obayashi C; Inaba M; Kiyooka K; Kanki M; Okita Y
    Chest; 2001 Aug; 120(2):589-94. PubMed ID: 11502663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
    Safran H; King T; Choy H; Gollerkeri A; Kwakwa H; Lopez F; Cole B; Myers J; Tarpey J; Rosmarin A
    Cancer; 1996 Sep; 78(6):1203-10. PubMed ID: 8826941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
    King TC; Akerley W; Fan AC; Moore T; Mangray S; Hsiu Chen M; Safran H
    Cancer; 2000 Aug; 89(4):769-73. PubMed ID: 10951339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
    Riely GJ; Gadgeel S; Rothman I; Saidman B; Sabbath K; Feit K; Kris MG; Rizvi NA
    Lung Cancer; 2007 Feb; 55(2):181-5. PubMed ID: 17092603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
    Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
    J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutations predict non-small cell lung carcinoma response to radiotherapy.
    Matsuzoe D; Hideshima T; Kimura A; Inada K; Watanabe K; Akita Y; Kawahara K; Shirakusa T
    Cancer Lett; 1999 Jan; 135(2):189-94. PubMed ID: 10096428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
    Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
    Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.
    Otani M; Natsume T; Watanabe JI; Kobayashi M; Murakoshi M; Mikami T; Nakayama T
    Jpn J Cancer Res; 2000 Aug; 91(8):837-44. PubMed ID: 10965026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the p53 gene in carcinomas of the urinary system.
    Suzuki Y; Tamura G
    Acta Pathol Jpn; 1993 Dec; 43(12):745-50. PubMed ID: 8109252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents.
    Watanabe J; Natsume T; Kobayashi M
    Anticancer Drugs; 2007 Sep; 18(8):905-11. PubMed ID: 17667596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.